Randomized phase 3 study of first-line AZD3759 (zorifertinib) versus gefitinib or erlotinib in EGFR-mutant (EGFRm+) non–small-cell lung cancer (NSCLC) with …
YL Wu, Q Zhou, J Wang, Y Yu, L Xing, Y Wang… - 2023 - ascopubs.org
9001 Background: Patients (pts) with EGFR m+ NSCLC have high rates of CNS metastasis,
few treatment options, and a poor prognosis. So far there are no solid evidence from head to …
few treatment options, and a poor prognosis. So far there are no solid evidence from head to …
Phase I study of AZD3759, a CNS penetrable EGFR inhibitor, for the treatment of non-small-cell lung cancer (NSCLC) with brain metastasis (BM) and leptomeningeal …
MJ Ahn, DW Kim, TM Kim, CC Lin, J Ratnayake… - 2016 - ascopubs.org
9003 Background: AZD3759 was the first EGFR inhibitor primarily designed to effectively
across the blood brain barrier to tackle central nervous system (CNS) metastases in patients …
across the blood brain barrier to tackle central nervous system (CNS) metastases in patients …
Efficacy, safety and dose selection of AZD3759 in patients with untreated EGFR-mutated non-small-cell lung cancer and central nervous system metastases in China …
SYM Liu, XR Dong, Z Wang, Y Du, JW Cui, Q Chu… - …, 2023 - thelancet.com
Background Central nervous system (CNS) metastases is inevitable for epidermal growth
factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). AZD3759 is a novel …
factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). AZD3759 is a novel …
Survival outcomes and symptomatic central nervous system (CNS) metastasis in EGFR-mutant advanced non-small cell lung cancer without baseline CNS metastasis …
Y Zhou, B Wang, J Qu, F Yu, Y Zhao, S Li, Y Zeng… - Lung Cancer, 2020 - Elsevier
Objectives Central nervous system (CNS) metastases are common complications in
epidermal growth factor receptor (EGFR) mutant non-small-cell lung cancer (NSCLC) …
epidermal growth factor receptor (EGFR) mutant non-small-cell lung cancer (NSCLC) …
AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases
Z Yang, Q Guo, Y Wang, K Chen, L Zhang… - Science translational …, 2016 - science.org
Non–small-cell lung cancer patients with activating mutations in epidermal growth factor
receptor (EGFR) respond to EGFR tyrosine kinase inhibitor (TKI) treatment. Nevertheless …
receptor (EGFR) respond to EGFR tyrosine kinase inhibitor (TKI) treatment. Nevertheless …
Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer
K Liu, G Jiang, A Zhang, Z Li, J Jia - BMC cancer, 2020 - Springer
Background The prognosis of non-small-cell lung cancer (NSCLC) with brain metastases is
very poor. Currently, therapeutic methods for this patient population include whole-brain …
very poor. Currently, therapeutic methods for this patient population include whole-brain …
First-versus third-generation EGFR tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer patients with brain metastases
Simple Summary Targeted therapies have emerged as newer systemic options for certain
cancers. EGFR-directed Tyrosine Kinase Inhibitors (EGFR-TKIs), which have several …
cancers. EGFR-directed Tyrosine Kinase Inhibitors (EGFR-TKIs), which have several …
[HTML][HTML] A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or …
Background Up to 40% of patients with non-small-cell lung cancer (NSCLC) and epidermal
growth factor receptor (EGFR) mutations treated with EGFR tyrosine kinase inhibitors (TKIs) …
growth factor receptor (EGFR) mutations treated with EGFR tyrosine kinase inhibitors (TKIs) …
[HTML][HTML] Improving outcomes for brain metastases in EGFR mutated NSCLC
JW Carlisle, SS Ramalingam - Translational Lung Cancer …, 2019 - ncbi.nlm.nih.gov
© Translational lung cancer research. All rights reserved. Transl Lung Cancer Res 2019; 8
(Suppl 4): S355-S359| http://dx. doi. org/10.21037/tlcr. 2019.05. 08 by erlotinib, the median …
(Suppl 4): S355-S359| http://dx. doi. org/10.21037/tlcr. 2019.05. 08 by erlotinib, the median …
Medical Treatment Options for Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Suffering from Brain Metastases and …
M Hochmair - Targeted Oncology, 2018 - Springer
Brain metastases and/or leptomeningeal disease (LMD) with associated central nervous
system (CNS) metastases are known complications of advanced epidermal growth factor …
system (CNS) metastases are known complications of advanced epidermal growth factor …